Isis Pharmaceuticals, Inc.
Isis Pharmaceuticals, Inc.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.
Website URL : http://www.isispharm.com
Stock Ticker : ISIS
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.
Website URL : http://www.isispharm.com
Stock Ticker : ISIS
Isis has successfully commercialized the world’s first antisense drug and has 22 drugs in development. Isis’ drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer. Isis’ partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide.
© Copyright 2012. HealthcareFirms.com | Heathcare Company Web Directory - Theme by DirectoryPress 2.10 - Developed By Mark Fail Site Map | Terms & Conditions | Privacy Policy